International Congress on Hematologic Malignancies (HEM) 2024 PNH

International Congress on Hematologic Malignancies (HEM) 2024

Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years

Access Resources

Human Factors Validation Study for a Wearable, Single-Use Injector

Access Resources

Back to Conference Resources

PNH Congress Presentations

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.

International Congress on Hematologic Malignancies (HEM) 2024

Back to Conference Resources

Report an Adverse Event or Product complaint

Ask a Medical Question

Connect with an MSL

Landing